source
- Bayer to buy Perfuse Therapeutics for $300M upfrontBayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears to be Bayer’s first…Endpoints · 2mo ago↗ source
- Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressureA million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's pill had sales of 2.3 billion D…Endpoints · 2mo ago↗ source
- Opinion: STAT+: Ambiguous loss: a peculiar kind of grief in dementia careAmbiguous loss is at the heart of the dementia illness experience.STAT · 2mo ago↗ source